Using publicly available databases, we analyzed PSMD1 and PSMD3 expression in FLT3-mutated AML patients and found no significant difference in OS comparing patients with high versus low PSMD1 expression (Figure 1C). This evidence concerns the gene PSMD1 and acute myeloid leukemia.